Lisa A. Conte - May 17, 2024 Form 4 Insider Report for Jaguar Health, Inc. (JAGX)

Role
CEO and President, Director
Signature
_/s/ Lisa A. Conte
Stock symbol
JAGX
Transactions as of
May 17, 2024
Transactions value $
$0
Form type
4
Date filed
5/21/2024, 05:00 PM
Previous filing
Apr 17, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JAGX Common Stock Options Exercise +2.7K +58.59% 7.3K May 17, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JAGX Restricted stock units Options Exercise $0 -2.7K -50.01% $0.00 2.69K May 17, 2024 Common Stock 2.7K Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 On January 23, 2023, the issuer effected a 75-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "January 2023 Reverse Stock Split). Upon effectiveness of the January 2023 Reverse Stock Split, every 75 shares of voting common stock was automatically converted into one share of voting common stock.
F3 The restricted stock units were originally approved by the issuer's board of directors on March 28, 2022 and previously reported as covering 606,280 shares, but were adjusted to reflect the January 2023 Reverse Stock Split. The restricted stock units vest in three equal annual installments beginning on May 17, 2023. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice.